Int J Clinicopathol Correl. 2024; 8(2):41-48.

Original Research

Emerging Biomarkers in Early Disease Detection: A Narrative Review

Rahul Chandran C.H[1*]

Affiliation

[1] Assistant professor, Department of Pathology, Dr Somervell memorial CSI MCH, Karakonam.

***Corresponding Author**

Rahul Chandran C.H, Assistant professor, Department of Pathology, Dr Somervell memorial CSI MCH, Karakonam.

E-mail: rahulpathology5@gmail.com

Submitted: 18-Dec-2024
Revised: 24-Dec- 2024
Accepted: 26-Dec-2024
Published: 27-Dec-2024

Abstract

The early diagnosis of diseases is a fundamental aspect of contemporary medicine, crucial for enhancing patient prognosis and alleviating healthcare system burdens. Biomarkers—measurable indicators of biological processes or disease states—have emerged as pivotal tools in diagnostics. This review focuses on novel biomarkers for early detection in cancer, cardiovascular diseases, and inflammatory conditions, with a special emphasis on liquid biopsies, circulating tumor DNA (ctDNA), cardiac troponins, cytokines, and exosome-based markers. Furthermore, advancements in omics technologies and artificial intelligence are highlighted as transformative in this field. Despite their potential, challenges such as validation, standardization, and practical integration into clinical workflows persist. Addressing these challenges through collaborative research will ensure these biomarkers play a central role in disease diagnostics, ultimately advancing global healthcare outcomes.

Keywords: Biomarkers, Early disease detection, Pathological Process, Health Care, Artificial Intelligence.

How to cite this article: Shankar Srinivasan, Prevalence and Recurrence of Multiple Periapical Cysts in Uncontrolled Diabetic Patients: A Retrospective Observational Study, Int J Clinicopathol Correl. 2024; 8(2):40-48. 10.56501/10.56501/intjclinicopatholcorrel.v8i2.1199. Copyright © 2024 Rahul

Introduction

Early disease detection is a cornerstone of effective healthcare, significantly reducing mortality and morbidity while alleviating the economic strain on healthcare systems. For instance, early-stage cancer detection can improve survival rates by up to 90%, compared to less than 20% for advanced stages. Similarly, timely diagnosis of cardiovascular diseases through biomarkers like high-sensitivity troponins can reduce the risk of fatal outcomes by 50%. These measurable indicators of biological or pathological processes have become indispensable in modern medicine, offering applications in risk stratification, early diagnosis, and therapeutic monitoring. [1-3]

Recent advancements in molecular biology and analytical technologies have accelerated biomarker discovery, with innovations such as circulating tumor DNA (ctDNA), microRNAs (miRNAs), and high-sensitivity troponins redefining diagnostics in cancer and cardiovascular diseases. Inflammatory conditions, too, have seen breakthroughs through the identification of specific cytokines and chemokines, enhancing our understanding of disease mechanisms and progression.[4,5]

This review underscores the transformative potential of emerging biomarkers, driven by technological advancements in omics, artificial intelligence, and point-of-care diagnostics. Despite these advancements, challenges such as validation, standardization, and clinical integration persist. Addressing these issues is critical for translating biomarker discoveries into routine clinical practice. With continued research and collaboration, biomarkers hold the promise to revolutionize global healthcare, enabling earlier interventions, improved patient outcomes, and reduced healthcare costs.

Review of Biomarkers in Cancer Diagnosis

1. Liquid Biopsies and Circulating Biomarkers:

Liquid biopsies represent a paradigm shift in cancer diagnostics by enabling the detection of tumor-derived components in blood or other body fluids. Circulating tumor DNA (ctDNA), for instance, is a fragment of tumor DNA shed into the bloodstream, offering a non-invasive means to detect cancer. Advanced technologies like next-generation sequencing (NGS) have significantly enhanced the sensitivity and specificity of ctDNA analysis. This allows for the early detection of cancers, monitoring of tumor dynamics, and identification of therapeutic resistance.

Circulating Tumor Cells (CTCs), although less abundant than ctDNA, provide valuable information about tumor progression and metastatic potential. The real-time monitoring capabilities of these biomarkers make them indispensable tools in precision oncology. However, challenges such as the rarity of CTCs and the high cost of detection technologies remain obstacles to widespread clinical adoption. [6]

2. Protein-Based Biomarkers:

Protein-based biomarkers are among the earliest forms of cancer diagnostics. Prostate-specific antigen (PSA), for example, has been instrumental in the early detection and management of prostate cancer. Similarly, Cancer Antigen- 125 (CA-125) and Human Epididymis Protein 4 (HE4) are routinely used in ovarian cancer diagnostics, aiding in disease staging and response evaluation. These proteins serve as measurable indicators of tumor burden and progression, allowing clinicians to make informed treatment decisions.

Despite their success, protein biomarkers are not without limitations. For instance, false positives can occur due to non-malignant conditions that elevate biomarker levels. Advances in proteomics and multi-biomarker panels are addressing these challenges by improving specificity and reducing diagnostic ambiguities. [7-9]

3. MicroRNAs (miRNAs):

MicroRNAs (miRNAs) are tiny, non-coding RNA molecules that play a crucial role in regulating gene expression. Abnormal miRNA patterns have been associated with the development and progression of several cancers, such as breast, lung, and colorectal cancers. Their detection in readily available body fluids, including blood and saliva, highlights their potential as non-invasive diagnostic markers.

Recent advancements in sequencing technologies have enabled the identification of cancer-specific miRNA signatures. These signatures provide insights into tumor biology, including its aggressiveness and metastatic potential. Moreover, miRNAs exhibit high stability in biological samples, making them suitable for use in routine diagnostics. Their integration into clinical workflows has the potential to revolutionize cancer management by enabling early detection and personalized therapeutic approaches. [8]

Biomarkers in Cardiovascular Diseases (CVDs)

1. Troponins:

Troponins, specifically cardiac troponin I (cTnI) and T (cTnT), are widely recognized as the gold standard for diagnosing myocardial infarction. High-sensitivity assays have further refined their diagnostic capabilities, allowing clinicians to detect even minor cardiac injuries. This has been particularly useful in acute coronary syndromes, where early identification of myocardial damage is critical for guiding treatment.

Beyond acute settings, troponins are increasingly being used to monitor chronic cardiovascular conditions. Their levels provide valuable prognostic information, enabling risk stratification and long-term management. However, interpreting troponin levels requires careful consideration of clinical context to avoid misdiagnosis, as elevated levels can also be observed in non-cardiac conditions such as sepsis or renal dysfunction. [10,11]

2. Natriuretic Peptides:

B-type Natriuretic Peptide (BNP) and its precursor, NT-proBNP, are essential in the diagnosis and management of heart failure. These biomarkers are released in response to ventricular pressure and volume overload, making them reliable indicators of cardiac dysfunction. Elevated levels are not only diagnostic but also prognostic, helping to predict outcomes and guide treatment strategies in heart failure patients. [12]

3. Inflammatory Biomarkers:

Inflammatory processes play a significant role in cardiovascular diseases, and biomarkers like C-reactive protein (CRP) and interleukin-6 (IL-6) are valuable in assessing cardiovascular risk. High-sensitivity CRP (hs-CRP) has been associated with an increased risk of atherosclerotic events. These markers provide insights into the underlying inflammatory mechanisms, enabling early detection and intervention. [12-15]

Biomarkers in Inflammatory Conditions

Inflammatory conditions encompass a wide range of diseases characterized by the activation of the immune system, often leading to tissue damage and systemic effects. Biomarkers are essential tools for understanding the underlying pathophysiology, monitoring disease progression, and guiding therapeutic interventions. Key categories of inflammatory biomarkers include:

1. Acute Phase Reactants:

Acute phase reactants (APRs) are proteins whose levels in the blood fluctuate during inflammatory responses. Notable examples include Erythrocyte Sedimentation

Rate (ESR) and C-reactive protein (CRP). ESR assesses how quickly red blood cells settle at the bottom of a tube within a defined timeframe. Elevated ESR levels indicate systemic inflammation and are used to monitor diseases like rheumatoid arthritis and systemic lupus erythematosus. CRP is produced by the liver in response to inflammatory cytokines such as interleukin-6 (IL-6). High-sensitivity CRP (hs-CRP) is a more refined measure used in cardiovascular and inflammatory diseases. The rapid rise and fall of CRP levels make it an effective marker for tracking acute inflammatory responses and treatment efficacy. [16,17]

2. Cytokines and Chemokines:

Cytokines and chemokines are signalling molecules essential for regulating immune responses and are key contributors to chronic inflammatory diseases. Tumour Necrosis Factor-alpha (TNF-α), a pro-inflammatory cytokine, plays a pivotal role in driving inflammation in disorders such as rheumatoid arthritis, inflammatory bowel disease (IBD), and psoriasis. Targeting TNF-α with monoclonal antibodies has revolutionized treatment for these diseases. IL-1β mediates acute and chronic inflammation, contributing to tissue damage and disease progression. IL-1β inhibitors are effective in treating autoinflammatory syndromes and gout. IL-6 plays a dual role in promoting inflammation and regulating immune responses. Elevated IL-6 levels are associated with conditions such as rheumatoid arthritis, sepsis, and COVID-19. IL-6 inhibitors are used to manage severe inflammatory conditions. [16-20]

3. Exosome-Based Biomarkers:

Exosomes are tiny extracellular vesicles that transport bioactive molecules, such as proteins, lipids, and nucleic acids, facilitating cell-to-cell communication and mirroring the physiological state of their originating cells. Exosomes carrying pro-inflammatory cytokines like Tumour Necrosis Factor (TNF-α) and IL-6 act as non-invasive biomarkers, aiding in tracking disease progression. Their role in diseases such as rheumatoid arthritis, multiple sclerosis, and Inflammatory Bowel Disease (IBD) is being extensively studied. Exosome-based diagnostic platforms are emerging, offering promising avenues for personalized medicine by detecting early molecular changes in inflammatory diseases. [21-23]

Advances in Biomarker Discovery

The discovery and validation of biomarkers are undergoing a revolution, driven by advancements in technology and a deeper understanding of molecular biology. These innovations are paving the way for highly specific, sensitive, and personalized diagnostic tools.

1. Omics Technologies:

Omics approaches, encompassing genomics, proteomics, and metabolomics, provide comprehensive insights into the molecular underpinnings of diseases. Focuses on identifying genetic variations, such as single nucleotide polymorphisms (SNPs) and mutations, associated with diseases. For example, BRCA1/2 mutations are well-established genomic biomarkers for breast and ovarian cancer risk. Involves studying protein expression patterns to identify disease-specific biomarkers. Advances in mass spectrometry have enabled the identification of low-abundance proteins that could serve as early indicators of diseases like Alzheimer’s and Parkinson’s. Examine small molecules in biological samples, offering insights into metabolic alterations linked to diseases such as cancer, diabetes, and cardiovascular conditions. Metabolomics has uncovered biomarkers for early-stage liver disease and metabolic syndrome. [24]

2. Artificial Intelligence and Machine Learning:

The application of AI and ML is transforming biomarker discovery and validation. AI algorithms analyze complex datasets, identifying subtle patterns and correlations that traditional methods may overlook. ML models can predict disease risks based on multi-biomarker panels, improving diagnostic precision. For instance, AI-driven platforms are being used to detect early signs of cancer using liquid biopsy data. Predictive analytics powered by AI has shown promise in identifying patients at risk for cardiovascular events, enabling proactive interventions. Single cell sequencing and analysis techniques have advanced our understanding of disease heterogeneity. These methods allow researchers to identify cell-specific biomarkers and pathways involved in disease progression. In oncology, single-cell RNA sequencing has been used to profile tumor microenvironments, uncovering novel therapeutic targets. [25,26]

3. Point-of-Care Testing (POCT):

Point-of-care testing (POCT) represents a leap forward in bringing diagnostics closer to patients. Portable devices and biosensors allow for rapid, on-site analysis of biomarkers, reducing delays associated with centralized laboratory testing. POCT is particularly valuable in resource-limited settings, enabling timely diagnosis and management of infectious diseases, diabetes, and cardiovascular conditions. Emerging POCT platforms leverage microfluidic technologies, enhancing their accuracy and usability.[27]

Challenges and Future Directions:

Despite significant progress in the discovery and development of biomarkers, several challenges remain in their effective clinical application. A primary challenge is the validation of biomarkers, which often necessitates large-scale, longitudinal studies to confirm their specificity and sensitivity in diverse patient populations. The process of establishing robust validation protocols is complex and requires careful consideration of potential confounding factors that could influence biomarker performance. Additionally, standardization of biomarkers remains a critical issue, as there is a need to ensure consistent and reliable results across different laboratories, clinical settings, and patient demographics. This variability can impact the reproducibility of results, which is essential for clinical adoption. Another significant barrier is the integration of biomarkers into clinical practice. Despite promising preliminary data, the clinical utility of biomarkers must be rigorously confirmed through well-designed clinical trials. These trials should aim to demonstrate the biomarker's diagnostic and prognostic value, as well as its ability to improve clinical decision-making. Furthermore, regulatory hurdles and the need for cost-effective implementation also pose challenges to widespread clinical adoption.[28]

Looking toward the future, overcoming these obstacles will require increased interdisciplinary collaboration among researchers, clinicians, and technologists. The synergy between these groups is critical for the development of biomarkers that are not only scientifically sound but also clinically relevant. The application of advanced technologies, such as artificial intelligence (AI), machine learning, and high-throughput screening platforms, holds great promise for accelerating the discovery and validation of novel biomarkers. AI-driven algorithms, for example, have the potential to analyze vast amounts of biological data, identify patterns, and predict disease risk with unprecedented accuracy. [28-31]

Furthermore, the future of biomarker research is likely to be shaped by the rise of personalized medicine. Tailoring diagnostic and therapeutic interventions based on individual genetic and molecular profiles could lead to more accurate early disease detection and the development of more effective, personalized treatment plans. Such advances could significantly improve patient outcomes, particularly in complex, heterogeneous diseases such as cancer and cardiovascular conditions. As biomarker research continues to evolve, it will play an increasingly vital role in transforming disease diagnostics, prognostics, and treatment strategies.

Conclusion

Emerging biomarkers are at the forefront of transforming healthcare by enabling earlier and more accurate disease detection across various medical fields, including oncology, cardiology, and immunology. These biomarkers hold immense potential to not only improve diagnostic precision but also facilitate timely interventions and better disease monitoring. The future success of biomarkers in clinical practice will hinge on overcoming critical challenges such as validation, standardization, and robust clinical trial confirmation. Continued innovation, along with a focus on translational research, is crucial for bridging the gap between laboratory discoveries and practical clinical applications. As research progresses, biomarkers will play an increasingly pivotal role in shaping personalized healthcare, offering the possibility to revolutionize global healthcare systems by improving patient outcomes, reducing healthcare costs, and enabling more efficient disease management.

Acknowledgement: Nil

Conflict of interest: Nil

Source of funding: Nil

References

1. Ahmadizar F, Younossi ZM. Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus. Journal of Clinical Gastroenterology. 2025 Jan 1;59(1):36-46. http://dx.doi.org/10.1097/MCG.0000000000002079
2. Ozkan SA, Bakirhan NK, Mollarasouli F, editors. The Detection of Biomarkers: Past, Present, and the Future Prospects. Academic Press; 2021 Dec 5.
3. Sinduja P, Ramani P, Sekaran S. Quantitative Assessment of Receptors of Advanced Glycation End Products Expression in Tissue Samples from Patients with oral Submucous Fibrosis, Leukoplakia, and Oral Squamous Cell Carcinoma. Contemporary Clinical Dentistry. 2024 Apr 1;15(2):71-6. http://dx.doi.org/10.4103/ccd.ccd_427_23
4. Salgia R. Oncology in the Precision Medicine Era. Springer International Publishing; 2020.
5. Carini C, Fidock M, van Gool A, editors. Handbook of biomarkers and precision medicine. Taylor & Francis; 2019 Apr 16.
6. Carini C, Fidock M, van Gool A, editors. Handbook of biomarkers and precision medicine. Taylor & Francis; 2019 Apr 16.
7. Bedore S, van der Eerden J, Boghani F, Patel SJ, Yassin S, Aguilar K, Lokeshwar VB. Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer—A Systematic Review of the Current Status. International Journal of Molecular Sciences. 2024 Sep 13;25(18):9899. http://dx.doi.org/10.3390/ijms25189899
8. Fagoonee S, Weiskirchen R. MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies. Cells. 2024 Nov 21;13(23):1935. http://dx.doi.org/10.3390/cells13231935
9. Park S, Kim D, Lee H, Hong CH, Son SJ, Roh HW, Kim D, Nam Y, Lee DG, Shin H, Woo HG. Plasma protein-based identification of neuroimage-driven subtypes in mild cognitive impairment via protein-protein interaction aware explainable graph propagational network. Computers in Biology and Medicine. 2024 Dec 1;183:109303. http://dx.doi.org/10.1016/j.compbiomed.2024.109303
10. Cretoiu S. Exosomes in cardiovascular diseases: biomarkers, pathological and

therapeutic effects. Springer.; 2017.
11. Bhatnagar S, Jain M. Unveiling the role of biomarkers in cardiovascular risk assessment and prognosis. Cureus. 2024 Jan;16(1). http://dx.doi.org/10.7759/cureus.51874
12. Haybar H, Bandar B, Torfi E, Mohebbi A, Saki N. Cytokines and their role in cardiovascular diseases. Cytokine. 2023 Sep 1;169:156261. http://dx.doi.org/10.1016/j.cyto.2023.156261
13. John RV, Devasiya T, VR N, Adigal S, Lukose J, Kartha VB, Chidangil S. Cardiovascular biomarkers in body fluids: Progress and prospects in optical sensors. Biophysical Reviews. 2022 Aug;14(4):1023-50. http://dx.doi.org/10.1007/s12551-022-00990-2
14. Chou PR, Wu PY, Wu PH, Huang TH, Huang JC, Chen SC, Lee SC, Kuo MC, Chiu YW, Hsu YL, Chang JM. Investigation of the Relationship between Cardiovascular Biomarkers and Brachial–Ankle Pulse Wave Velocity in Hemodialysis Patients. Journal of Personalized Medicine. 2022 Apr 15;12(4):636. http://dx.doi.org/10.3390/jpm12040636
15. Kansestani AN, Zare ME, Zhang J. Prognostic Accuracy of Cardiovascular Disease Biomarkers in Patients with COVID-19: A Diagnostic Test Accuracy Meta-analysis. The Journal of Tehran University Heart Center. 2021 Jan;16(1):1. http://dx.doi.org/10.18502/jthc.v16i1.6594
16. Ding Z, Zhou W, Wang D, Li L, Wang C, Wang C. MRI variables and peripheral inflammatory response biomarkers predict severity and prognosis in patients with acute cervical traumatic spinal cord injury. BMC Musculoskeletal Disorders. 2024 Nov 12;25(1):900. http://dx.doi.org/10.1186/s12891-024-08038-0
17. Lachman ME, Schiloski KA. The psychosocial anti-inflammatories: Sense of control, purpose in life, and social support in relation to inflammation, functional health and chronic conditions in adulthood. Journal of psychosomatic research. 2024 Dec 1;187:111957. http://dx.doi.org/10.1016/j.jpsychores.2024.111957
18. Mackiewicz A, Kushner I, Baumann H. Acute phase proteins molecular biology, biochemistry, and clinical applications. CRC Press; 2020 Jul 24.
19. Chamani A, Mashhadi F, Khademi G, Nematy M, Emadzadeh M, Sezavar M, Roudi F. Investigating the effect of synbiotic supplementation on inflammatory indices in critically ill septic children: a protocol study for randomized control trial. Trials. 2024 Oct 24;25(1):712. http://dx.doi.org/10.1186/s13063-024-08514-x
20. Azimudin R, Palati S, Priyadharshini R. Evaluating tumor necrosis factor (TNF)-alpha pro-inflammatory cytokines in healthy and oral squamous cell carcinoma patients with and without diabetes. Cureus. 2024 Jan;16(1). http://dx.doi.org/10.7759/cureus.52890
21. Ali KA, He L, Deng X, Pan J, Huang H, Li W. Assessing the predictive value of pre-and post-operative inflammatory markers in patients undergoing total knee arthroplasty. Journal of Orthopaedic Surgery and Research. 2024 Sep 30;19(1):614. http://dx.doi.org/10.1186/s13018-024-05104-0
22. Elmelid A, Vandikas MS, Gillstedt M, Alsterholm M, Osmancevic A. The Effect of Phototherapy on Systemic Inflammation Measured with Serum Vitamin D-Binding Protein and hsCRP in Patients with Inflammatory Skin Disease. International Journal of Molecular Sciences. 2024 Aug 8;25(16):8632. http://dx.doi.org/10.3390/ijms25168632
23. Hoffmann SW, Schierbauer J, Zimmermann P, Voit T, Grothoff A, Wachsmuth NB, Rössler A, Niedrist T, Lackner HK, Moser O. Effects of Interrupting Prolonged Sitting with Light-Intensity Physical Activity on

Inflammatory and Cardiometabolic Risk Markers in Young Adults with Overweight and Obesity: Secondary Outcome Analyses of the SED-ACT Randomized Controlled Crossover Trial. Biomolecules. 2024 Aug 19;14(8):1029. http://dx.doi.org/10.3390/biom14081029

24. Haghayegh F, Norouziazad A, Haghani E, Feygin AA, Rahimi RH, Ghavamabadi HA, Sadighbayan D, Madhoun F, Papagelis M, Felfeli T, Salahandish R. Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies. Advanced Science. 2024 Sep;11(36):2400595. http://dx.doi.org/10.1002/advs.202400595
25. Khanna A, El Barachi M, Jain S, Kumar M, Nayyar A, editors. Artificial Intelligence and machine learning in drug design and development. John Wiley & Sons; 2024 Jul 18.
26. Eftekhari M, Ma C, Orlov YL. Applications of artificial intelligence, machine learning, and deep learning in plant breeding. Frontiers in Plant Science. 2024 May 22;15:1420938.
27. Loiodice A, Bailly S, Ruckly S, Buetti N, Barbier F, Staiquly Q, Tabah A, Timsit JF, Lipman J, Pollock H, Margetts B. Effect of adequacy of empirical antibiotic therapy for hospital-acquired bloodstream infections on intensive care unit patient prognosis: a causal inference approach using data from the Eurobact2 study. Clinical Microbiology and Infection. 2024 Dec 1;30(12):1559-68.http://dx.doi.org/10.1016/j.cmi.2024.09.011
28. Ahangar M, Mahjoubi F, Mowla SJ. Bladder cancer biomarkers: current approaches and future directions. Frontiers in Oncology. 2024 Nov 29;14:1453278. http://dx.doi.org/10.3389/fonc.2024.1453278
29. Sheffield Z, Paul P, Krishnakumar S, Pan D. Current Strategies and Future Directions of Wearable Biosensors for Measuring Stress Biochemical Markers for Neuropsychiatric Applications. Advanced Science.:2411339.http://dx.doi.org/10.1002/advs.202411339
30. Chen J, Zhang Y, Lin Z, Peng Y, Madan A, Cai S, Lin Z, Shen Y, Chen Y, Xu Y, Wu J. Prognostic value of ubiquitination-related differentially expressed genes in esophageal squamous cell carcinoma: a comprehensive analysis and future directions. Journal of Thoracic Disease. 2024 Nov 29;16(11):7866.http://dx.doi.org/10.21037/jtd-24-1863
31. de Oliveira AA, Benvindo-Souza M, Dos Santos HV, Barradas MC, Marques LP, Costa AG, Sarmento RA, e Silva DD, de Souza Saraiva A. The impact of neonicotinoid insecticides on amphibians: A comprehensive review and future research challenges. Environmental Research. 2024 Dec 10:120595. http://dx.doi.org/10.1016/j.envres.2024.120595